300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Hong Kong
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Carma Fund, VC Fund

Carma Fund

VC Fund

Munich, Germany

Carma Fund is an early-stage investment fund for advancing life science and healthcare technologies.

Total investments:
12
Last investment:
Lead investor:
33%

Last updated:

Industries Carma Fund invests in

Health CareBiotechnologyMedical DeviceHealth DiagnosticsMedical

Stages Carma Fund invests in

SeedSeries ASeries BPre-Seed

Countries Carma Fund invests in

GermanyFranceSwedenSwitzerland

Round sizes

Seed $2.8M–$13MSeries A $4.4M–$12MSeries B $34M–$62M

Round size

Seed
$2.8M–$13M
Series A
$4.4M–$12M
Series B
$34M–$62M

Investment Focus

Industry

  • Health Care 8 (67%)
  • Biotechnology 4 (33%)
  • Medical Device 3 (25%)
  • Health Diagnostics 3 (25%)
  • Medical 2 (17%)
See all 19 industries →

Stage

  • Seed 7 (58%)
  • Series A 2 (17%)
  • Series B 2 (17%)
  • Pre-Seed 1 (8%)

Country

  • Germany 8 (67%)
  • France 1 (8%)
  • Sweden 1 (8%)
  • Switzerland 1 (8%)

Investments

CompanyDescriptionRoundLinks
Kupando Kupando
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. $11.5M / Series A / Mar 18, 2026
Exciva Exciva
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. $62.2M / Series B / Jan 20, 2026
TECregen TECregen
TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses. $12.5M / Seed / Jan 08, 2026
Elkedonia Elkedonia
Elkedonia is a biotech company dedicated to transforming antidepressant therapy. It aims to develop a groundbreaking antidepressant treatment that is accessible, fast-acting, and free from the risks of dependence, sedation, or psychotic effects. $12.9M / Seed / Jun 11, 2025
Akribion Genomics Akribion Genomics
Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology. $8.3M / Seed / Feb 04, 2025
Aignostics Aignostics
Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis. $34M / Series B / Oct 29, 2024
Symphera Symphera
Symphera provides an all-in-one surgical system that makes minimally-invasive procedures more efficient. $2.8M / Seed / Sep 16, 2024
Thryve Thryve
Thryve’s SDK brings everything you need to access fragmented wearable, medical devices, and health data silos with a single integration. We unify your users’ data from smartwatches, blood glucose meters, and many other sources that unlock a continuous stream of harmonized health information for your care. We support popular data sources like AppleHealth, Google Fit, Huawei Health, Samsung Health, and many more. $4.4M / Series A / Aug 30, 2024
Allogenetics Allogenetics
Allogenetics GmbH provides a unique solution to the problem of organ rejection following transplantation. It is a distinct first-in-class therapy since it addresses the transplant rather than paralyzing the patient's immune system. $3.8M / Seed / Aug 29, 2024
Heidelberg Epignostix Heidelberg Epignostix
Heidelberg Epignostix is a pioneering start-up led by a dedicated team of DNA methylation-based tumor categorization experts. Heidelberg Epignostix has revolutionized tumor categorization by using the strength of methylation-based algorithms. $4.6M / Seed / Jul 02, 2024
See all 12 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Hong Kong
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Carma Fund invest in?

Carma Fund invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Carma Fund invest in?

Carma Fund typically joins rounds of $2.8M–$13M at Seed, $4.4M–$12M at Series A and $34M–$62M at Series B. These are whole funding-round sizes, not Carma Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Carma Fund took part in.

When did Carma Fund last invest?

The most recent investment recorded for Carma Fund closed in Mar 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Carma Fund Carma Fund Find emails